Myeloid neoplasms after breast cancer: "Therapy-related" not an independent poor prognostic factor

Yiming Chen, Zeev Estrov, Sherry Pierce, Wei Qiao, Gautam Borthakur, Farhad Ravandi, Tapan Kadia, Mark Brandt, Susan O'brien, Elias Jabbour, Guillermo Garcia-Manero, Jorge Cortes, Miloslav Beran

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

Abstract Two hundred and thirty-five consecutive patients presenting to a single center with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after breast cancer treatment were compared with matched patients with de novo AML or MDS. There was no significant difference in median overall survival (OS) times between patients with therapy-related AML and those with de novo AML (8.7 months vs.10.2 months; p = 0.17). Patients with therapy-related MDS had slightly lower median baseline platelet counts and a higher frequency of poor cytogenetics than those with de novo MDS, but the two groups had similar OS times (13.6 months vs. 18.9 months; p = 0.06). Multivariate analysis revealed that cytogenetic risk, baseline white blood cell count, age and performance status were predictive for OS time in AML and that cytogenetic risk and performance status were predictive for OS time in MDS. Having therapy-related disease is not an independent risk factor in patients with myeloid neoplasms and with a history of breast cancer. Clinical trials should be designed to serve both populations.

Original languageEnglish (US)
Pages (from-to)1012-1019
Number of pages8
JournalLeukemia and Lymphoma
Volume56
Issue number4
DOIs
StatePublished - Apr 1 2015
Externally publishedYes

Keywords

  • Chemotherapeutic approaches
  • Myeloid leukemias and dysplasias
  • Prognostication

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Myeloid neoplasms after breast cancer: "Therapy-related" not an independent poor prognostic factor'. Together they form a unique fingerprint.

  • Cite this

    Chen, Y., Estrov, Z., Pierce, S., Qiao, W., Borthakur, G., Ravandi, F., Kadia, T., Brandt, M., O'brien, S., Jabbour, E., Garcia-Manero, G., Cortes, J., & Beran, M. (2015). Myeloid neoplasms after breast cancer: "Therapy-related" not an independent poor prognostic factor. Leukemia and Lymphoma, 56(4), 1012-1019. https://doi.org/10.3109/10428194.2014.946023